Dr. Thomas Folliard

Dr. Thomas Folliard

Chief Executive Officer

Tom received his PhD in Biochemistry from the University of Oxford, as well as his Master of Research in Synthetic Biology from University College London. His research spanned several domains of fundamental biochemistry, synthetic biology, engineering, and space science in conjunction with NASA's Ames Research Center.

Dr. Barbara Mertins

Dr. Barbara Mertins

Chief Scientific Officer

Barbara received her PhD (Dr. rer. nat.) in Biochemistry from the Philipps University of Marburg in Germany. She then joined the University of Oxford as a Postdoctoral Research Associate, studying the structural biology of complex membrane proteins.

After her postdoctoral research, Barbara worked as a Senior Scientist at Evotec, a contract drug development company. Her time at Evotec gave her deeper insights into the challenges of protein production in drug discovery.


Professor Chas Bountra

Dr. Chas Bountra is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He previously served as Vice President and Head of Biology at GlaxoSmithKline, where he was involved in the development of the first treatment for IBD and the identification of more than 40 clinical candidates for GI, inflammatory, and neuro-psychiatric diseases.


Professor John Ward

Dr. John Ward is Professor of Synthetic Biology for Bioprocessing in the Department of Biochemical Engineering at University College London. He founded the university's MRe program in Synthetic Biology and its MSc program in Applied Molecular Biology and Biotechnology. His research is focused on the use of bacteria to develop new chemicals, pathways, and active entities for synthetic biology applications.

We are rethinking how to interact with biology to advance science.

ExcepGen was founded by two scientists who believe that the key to scientific progress lies in challenging the dominant theory about what is — and what is not — possible.